Federation des caisses Desjardins du Quebec’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Federation des caisses Desjardins du Quebec’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,460	Closed	-$3.07K	–	2420
2022 Q4	$3.07K	Sell	3,460 -1,000	-22%	-$1.33K	﹤0.01%	2136
2022 Q3	$7K	Hold	4,460	–	–	﹤0.01%	1998
2022 Q2	$8.96K	Sell	4,460 -1,540	-26%	-$2.66K	﹤0.01%	1988
2022 Q1	$14K	Sell	6,000 -1,000	-14%	-$3.12K	﹤0.01%	1926
2021 Q4	$32.5K	Buy	7,000 +1,000	+17%	+$6.21K	﹤0.01%	1704
2021 Q3	$45.8K	Hold	6,000	–	–	﹤0.01%	1625
2021 Q2	$58.1K	Sell	6,000 -4,300	-42%	-$34.2K	﹤0.01%	1567
2021 Q1	$85.2K	Buy	10,300 +7,800	+312%	+$82.4K	﹤0.01%	1392
2020 Q4	$17.1K	Sell	2,500 -500	-17%	-$4.02K	﹤0.01%	1782
2020 Q3	$33.5K	Buy	3,000 +1,500	+100%	+$13.7K	﹤0.01%	1351
2020 Q2	$9.42K	Buy	+1,500	New	+$5.74K	﹤0.01%	1655

Other funds holding SRNE

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

OFA

Oaktree Fund Advisors Los Angles, California $56.9M AUM 80.32% 1-Year Est. Return

CGA

Crescent Grove Advisors Lake Forest, Illinois $1.04B AUM 17.78% 1-Year Est. Return

LCM

Lattice Capital Management Kirkland, Washington $56.9M AUM 49.15% 1-Year Est. Return

STB

S&T Bank Indiana, Pennsylvania $268M AUM 39.92% 1-Year Est. Return

GoalVest Advisory New York $539M AUM 27.49% 1-Year Est. Return

HFRG

Houlihan Financial Resource Group Ashburn, Virginia $257M AUM 14.19% 1-Year Est. Return

VFA

Valeo Financial Advisors Carmel, Indiana $4.74B AUM 27.69% 1-Year Est. Return

GBWM

Granite Bay Wealth Management Portsmouth, New Hampshire $470M AUM 15.4% 1-Year Est. Return

Federation des caisses Desjardins du Quebec's SRNE Position: Q1 2023 in Review

Federation des caisses Desjardins du Quebec sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2023, closing a stake of 3,460 shares — an estimated $3.07K sold.

Federation des caisses Desjardins du Quebec first reported a position in SRNE in Q2 2020 and held it in 11 quarters. The position peaked at $85.2K in Q1 2021. 34 funds tracked by Wall St. Rank hold SRNE as of Q1 2023.

Federation des caisses Desjardins du Quebec reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2023 after selling out during the quarter.
Federation des caisses Desjardins du Quebec sold 3,460 Sorrento Therapeutics, Inc. shares in Q1 2023, an estimated $3.07K.
Federation des caisses Desjardins du Quebec first reported a position in Sorrento Therapeutics, Inc. in Q2 2020 and held it in 11 quarters.
Federation des caisses Desjardins du Quebec's Sorrento Therapeutics, Inc. position peaked at $85.2K in Q1 2021.
34 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2023.

Based on Federation des caisses Desjardins du Quebec's 13F filing for Q1 2023, filed 15 Aug 2024.